David is a physician-scientist, an Assistant Professor at the Yale School of Medicine, a Goodman and Gilman Yale Scholar, and a principal investigator in the Center of Molecular and Cellular Oncology within the Yale Cancer Center. He completed a clinical fellowship in Medical Oncology and post-doctoral fellowship at Dana-Farber Cancer Institute and Harvard Medical School, where he was the Emil Frei Fellow, the John R. Svenson Fellow, and served as an Instructor of Medicine. He was selected to be part of the Department of Defense’s Academy of Kidney Cancer Investigator, the Immuno-Oncology Young Investigator’s Forum and the SITC Sparkathon for Emerging Leaders Igniting Innovation in cancer immunotherapy. In 2019, he was named a “NextGen Innovator” by HemOnc Today, in 2022 he received the Kidney Cancer Association “Trailblazer Award”, and in 2023 he received the “Young Physician-Scientist” Award from the American Society of Clinical Investigation (ASCI) and an R37 MERIT Award through the NIH/NCI. Through combined experimental and computational approaches, he aims to better understand the key determinants of anti-tumor immunity in order to develop novel therapies for patients with advanced cancer.